Beta3-Adrenergic Receptors in Cardiac and Vascular Tissues. Emerging Concepts and Therapeutic Perspectives

Advances in Pharmacology

Volumn 59, Issue C, 2010, Pages 135-163

  Dessy, Chantal ^a   Balligand, Jean Luc ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Beta3 adrenoceptor; Cardiac; Vascular

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

AORTA; BLOOD VESSEL; BOOK; HEART; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; UPREGULATION; VASODILATATION; ADRENERGIC SYSTEM; ANIMAL; ANIMAL MODEL; DOG; DRUG EFFECTS; HEART CONTRACTION; HEART FAILURE; HYPERTENSION; INNERVATION; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT;

ADRENERGIC BETA-3 RECEPTOR AGONISTS; ADRENERGIC BETA-3 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOOD VESSELS; DOGS; HEART; HEART FAILURE; HUMANS; HYPERTENSION; MICE; MODELS, ANIMAL; MYOCARDIAL CONTRACTION; RATS; RECEPTORS, ADRENERGIC, BETA-3; SYMPATHETIC NERVOUS SYSTEM; VASODILATION;

EID: 77957372042     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(10)59005-7     Document Type: Chapter

References (115)

1. Amour J., Loyer X., Le G.M., et al. Altered contractile response due to increased beta3-adrenoceptor stimulation in diabetic cardiomyopathy: The role of nitric oxide synthase 1-derived nitric oxide. Anesthesiology 2007, 107:452-460.
2. Atef N., Lafontan M., Double A., et al. A specific beta 3-adrenoceptor agonist induces increased pancreatic islet blood flow and insulin secretion in rats. European Journal of Pharmacology 1996, 298:287-292.
3. Arch J.R. Beta(3)-adrenoceptor agonists: potential, pitfalls and progress. European Journal of Pharmacology 2002, 440:99-107.
4. Arch J.R., Ainsworth A.T., Cawthorne M.A., et al. Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 1984, 309:163-165.
5. Balligand J.L. Beta(3)-adrenoceptor stimulation on top of beta(1)-adrenoceptor blockade "stop or encore?". Journal of the American College of Cardiology 2009, 53:1539-1542.
6. Balligand J.L., Feron O., Dessy C. ENOS activation by physical forces: From short-term regulation of contraction to chronic remodeling of cardiovascular tissues. Physiological Reviews 2009, 89:481-534.
7. Balligand J.L., Kelly R.A., Marsden P.A., et al. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:347-351.
8. Barbe P., Millet L., Galitzky J., et al. In situ assessment of the role of the beta 1-, beta 2- and beta 3-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue. British Journal of Pharmacology 1996, 117:907-913.
9. Barouch L.A., Harrison R.W., Skaf M.W., et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 2002, 416:337-339.
10. Berg T., Piercey B.W., Jensen J. Role of beta1-3-adrenoceptors in blood pressure control at rest and during tyramine-induced norepinephrine release in spontaneously hypertensive rats. Hypertension 2010, 55:1224-1230.
11. Berlan M., Galitzky J., Bousquet-Melou A., et al. Beta-3 adrenoceptor-mediated increase in cutaneous blood flow in the dog. The Journal of Pharmacology and Experimental Therapeutics 1994, 268:1444-1451.
12. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. The New England Journal of Medicine 2001, 344:1659-1667. Beta-Blocker Evaluation of Survival Trial Investigators.
13. Bianchetti A., Manara L. In vitro inhibition of intestinal motility by phenylethanolaminotetralines: Evidence of atypical beta-adrenoceptors in rat colon. British Journal of Pharmacology 1990, 100:831-839.
14. Birenbaum A., Tesse A., Loyer X., et al. Involvement of beta3-adrenoceptor in altered beta-adrenergic response in senescent heart: Role of nitric oxide synthase 1-derived nitric oxide. Anesthesiology 2008, 109:1045-1053.
15. Brahmadevara N., Shaw A.M., MacDonald A. Evidence against beta3-adrenoceptors or low affinity state of beta 1-adrenoceptors mediating relaxation in rat isolated aorta. British Journal of Pharmacology 2003, 138:99-106.
16. Brahmadevara N., Shaw A.M., MacDonald A. Alpha1-adrenoceptor antagonist properties of CGP 12177a and other beta-adrenoceptor ligands: Evidence against beta(3)- or atypical beta-adrenoceptors in rat aorta. British Journal of Pharmacology 2004, 142:781-787.
17. Brawley L., Shaw A.M., MacDonald A. Beta1-, beta2- and atypical beta-adrenoceptor-mediated relaxation in rat isolated aorta. British Journal of Pharmacology 2000, 129:637-644.
18. Briones A.M., Daly C.J., Jimenez-Altayo F., et al. Direct demonstration of beta1- and evidence against beta2- and beta3-adrenoceptors, in smooth muscle cells of rat small mesenteric arteries. British Journal of Pharmacology 2005, 146:679-691.
19. Brixius K., Bloch W., Ziskoven C., et al. Beta3-adrenergic eNOS stimulation in left ventricular murine myocardium. Canadian Journal of Physiology Pharmacology 2006, 84:1051-1060.
20. Burger D.E., Lu X., Lei M., et al. Neuronal nitric oxide synthase protects against myocardial infarction-induced ventricular arrhythmia and mortality in mice. Circulation 2009, 120:1345-1354.
21. Candelore M.R., Deng L., Tota L., et al. Potent and selective human beta(3)-adrenergic receptor antagonists. The Journal of Pharmacology and Experimental Therapeutics 1999, 290:649-655.
22. Cheng H.J., Zhang Z.S., Onishi K., et al. Upregulation of functional beta(3)-adrenergic receptor in the failing canine myocardium. Circulation Research 2001, 89:599-606.
23. Chruscinski A.J., Rohrer D.K., Schauble E., et al. Targeted disruption of the beta2 adrenergic receptor gene. The Journal of Biological Chemistry 1999, 274:16694-16700.
24. Cirino G., Sorrentino R., Di Villa B.R., et al. Involvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:5531-5536.
25. Clark B.J., Bertholet A. Effects of pindolol on vascular smooth muscle. General Pharmacology 1983, 14:117-119.
26. Cohen M.L., Bloomquist W., Kriauciunas A., et al. Aryl propanolamines: Comparison of activity at human beta3 receptors, rat beta3 receptors and rat atrial receptors mediating tachycardia. British Journal of Pharmacology 1999, 126:1018-1024.
27. de Groot A.A., Mathy M.J., van Zwieten P.A., et al. Involvement of the beta3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta. Journal of Cardiovascular Pharmacology 2003, 42:232-236.
28. Dennedy M.C., Houlihan D.D., McMillan H., et al. Beta2- and beta3-adrenoreceptor agonists: Human myometrial selectivity and effects on umbilical artery tone. American Journal of Obstetrics and Gynecology 2002, 187:641-647.
29. Dessy C., Moniotte S., Ghisdal P., et al. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation 2004, 110:948-954.
30. Dessy C., Saliez J., Ghisdal P., et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005, 112:1198-1205.
31. Dincer U.D., Bidasee K.R., Guner S., et al. The effect of diabetes on expression of beta1-, beta2-, and beta3-adrenoreceptors in rat hearts. Current Medical Literature-Diabetes 2001, 50:455-461.
32. Dolan J.A., Muenkel H.A., Burns M.G., et al. Beta-3 adrenoceptor selectivity of the dioxolane dicarboxylate phenethanolamines. The Journal of Pharmacology and Experimental Therapeutics 1994, 269:1000-1006.
33. Donckier J.E., Massart P.E., Van M.H., et al. Cardiovascular effects of beta 3-adrenoceptor stimulation in perinephritic hypertension. European Journal of Clinical Investigation 2001, 31:681-689.
34. Dumas M., Dumas J.P., Bardou M., et al. Influence of beta-adrenoceptor agonists on the pulmonary circulation. Effects of a beta3-adrenoceptor antagonist, SR 59230a. European Journal of Pharmacology 1998, 348:223-228.
35. Dumas J.P., Goirand F., Bardou M., et al. Role of potassium channels and nitric oxide in the relaxant effects elicited by beta-adrenoceptor agonists on hypoxic vasoconstriction in the isolated perfused lung of the rat. British Journal of Pharmacology 1999, 127:421-428.
36. Emorine L.J., Marullo S., Briend-Sutren M.M., et al. Molecular characterization of the human beta3-adrenergic receptor. Science 1989, 245:1118-1121.
37. Engelhardt S., Hein L., Wiesmann F., et al. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:7059-7064.
38. Evans B.A., Papaioannou M., Hamilton S., et al. Alternative splicing generates two isoforms of the beta3-adrenoceptor which are differentially expressed in mouse tissues. British Journal of Pharmacology 1999, 127:1525-1531.
39. Evans B.A., Sato M., Sarwar M., et al. Ligand-directed signalling at beta-adrenoceptors. British Journal of Pharmacology 2010, 159:1022-1038.
40. Flather M.D., Shibata M.C., Coats A.J., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal 2005, 26:215-225.
41. Galitzky J., Reverte M., Portillo M., et al. Coexistence of beta1-, beta2-, and beta3-adrenoceptors in dog fat cells and their differential activation by catecholamines. American Journal of Physiology 1993, 264:E403-E412.
42. Gauthier C., Leblais V., Kobzik L., et al. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. The Journal of Clinical Investigation 1998, 102:1377-1384.
43. Gauthier C., Tavernier G., Charpentier F., et al. Functional beta3-adrenoceptor in the human heart. The Journal of Clinical Investigation 1996, 98:556-562.
44. Gauthier C., Tavernier G., Trochu J.N., et al. Interspecies differences in the cardiac negative inotropic effects of beta(3)-adrenoceptor agonists. The Journal of Pharmacology and Experimental Therapeutics 1999, 290:687-693.
45. Germack R., Dickenson J.M. Induction of beta3-adrenergic receptor functional expression following chronic stimulation with noradrenaline in neonatal rat cardiomyocytes. The Journal of Pharmacology and Experimental Therapeutics 2006, 316:392-402.
46. Granneman J.G., Lahners K.N., Chaudhry A. Characterization of the human beta 3-adrenergic receptor gene. Molecular Pharmacology 1993, 44:264-270.
47. Granneman J.G., Lahners K.N., Rao D.D. Rodent and human beta3-adrenergic receptor genes contain an intron within the protein-coding block. Molecular Pharmacology 1992, 42:964-970.
48. Hutchinson D.S., Bengtsson T., Evans B.A., et al. Mouse beta3a- and beta 3b-adrenoceptors expressed in Chinese hamster ovary cells display identical pharmacology but utilize distinct signalling pathways. British Journal of Pharmacology 2002, 135:1903-1914.
49. Imbrogno S., Angelone T., Adamo C., et al. Beta3-adrenoceptor in the eel (Anguilla anguilla) heart: Negative inotropy and NO-cGMP-dependent mechanism. The Journal of Experimental Biology 2006, 209:4966-4973.
50. Jockers R., Da S.A., Strosberg A.D., et al. New molecular and structural determinants involved in beta2-adrenergic receptor desensitization and sequestration. Delineation using chimeric beta3/beta2-adrenergic receptors. The Journal of Biological Chemistry 1996, 271:9355-9362.
51. Kaumann A.J., Molenaar P. Differences between the third cardiac beta-adrenoceptor and the colonic beta3-adrenoceptor in the rat. British Journal of Pharmacology 1996, 118:2085-2098.
52. Kirstein M., Rivet-Bastide M., Hatem S., et al. Nitric oxide regulates the calcium current in isolated human atrial myocytes. The Journal of Clinical Investigation 1995, 95:794-802.
53. Kohout T.A., Takaoka H., McDonald P.H., et al. Augmentation of cardiac contractility mediated by the human beta(3)-adrenergic receptor overexpressed in the hearts of transgenic mice. Circulation 2001, 104:2485-2491.
54. Kozlowska H., Szymska U., Schlicker E., et al. Atypical beta-adrenoceptors, different from beta3-adrenoceptors and probably from the low-affinity state of beta1-adrenoceptors, relax the rat isolated mesenteric artery. British Journal of Pharmacology 2003, 140:3-12.
55. Kuratani K., Kodama H., Yamaguchi I. Enhancement of gastric mucosal blood flow by beta-3 adrenergic agonists prevents indomethacin-induced antral ulcer in the rat. The Journal of Pharmacology and Experimental Therapeutics 1994, 270:559-565.
56. Lands A.M., Arnold A., McAuliff J.P., et al. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967, 214:597-598.
57. Langin D., Portillo M.P., Saulnier-Blache J.S., et al. Coexistence of three beta-adrenoceptor subtypes in white fat cells of various mammalian species. European Journal of Pharmacology 1991, 199:291-301.
58. Larsen T.M., Toubro S., van Baak M.A., et al. Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. The American Journal of Clinical Nutrition 2002, 76:780-788.
59. Leblais V., Krisa S., Valls J., et al. Relaxation induced by red wine polyphenolic compounds in rat pulmonary arteries: Lack of inhibition by NO-synthase inhibitor. Fundamental & Clinical Pharmacology 2008, 22:25-35.
60. Lenzen G., Pietri-Rouxel F., Drumare M.F., et al. Genomic cloning and species-specific properties of the recombinant canine beta3-adrenoceptor. European Journal of Pharmacology 1998, 363:217-227.
61. Liggett S.B., Freedman N.J., Schwinn D.A., et al. Structural basis for receptor subtype-specific regulation revealed by a chimeric beta3/beta2-adrenergic receptor. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:3665-3669.
62. Liggett S.B., Mialet-Perez J., Thaneemit-Chen S., et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:11288-11293.
63. Lohse M.J., Engelhardt S., Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure?. Circulation Research 2003, 93:896-906.
64. MacDonald A., McLean M., MacAulay L., et al. Effects of propranolol and L-NAME on beta-adrenoceptor-mediated relaxation in rat carotid artery. Journal of Autonomic Pharmacology 1999, 19:145-149.
65. Maffei A., Di P.A., Carangi R., et al. Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation. Hypertension 2007, 50:652-656.
66. Mallem M.Y., Toumaniantz G., Serpillon S., et al. Impairment of the low-affinity state beta1-adrenoceptor-induced relaxation in spontaneously hypertensive rats. British Journal of Pharmacology 2004, 143:599-605.
67. Massion P.B., Balligand J.L. Modulation of cardiac contraction, relaxation and rate by the endothelial nitric oxide synthase (eNOS): Lessons from genetically modified mice. Journal of Physiology (Paris) 2003, 546:63-75.
68. Massion P.B., Dessy C., Desjardins F., et al. Cardiomyocyte-restricted overexpression of endothelial nitric oxide synthase (NOS3) attenuates beta-adrenergic stimulation and reinforces vagal inhibition of cardiac contraction. Circulation 2004, 110:2666-2672.
69. Moens A.L., Leyton-Mange J.S., Niu X., et al. Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor. Journal of Molecular and Cellular Cardiology 2009, 47:576-585.
70. Moniotte S., Belge C., Sekkali B., et al. Sepsis is associated with an upregulation of functional beta3 adrenoceptors in the myocardium. European Journal of Heart Failure 2007, 9:1163-1171.
71. Moniotte S., Vaerman J.L., Kockx M.M., et al. Real-time RT-PCR for the detection of beta-adrenoceptor messenger RNAs in small human endomyocardial biopsies. Journal of Molecular and Cellular Cardiology 2001, 33:2121-2133.
72. Morimoto A., Hasegawa H., Cheng H.J., et al. Endogenous beta3-adrenoreceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure. American Journal of Physiology-Heart and Circulatory Physiology 2004, 286:H2425-H2433.
73. Oriowo M.A. Atypical beta-adrenoceptors in the rat isolated common carotid artery. British Journal of Pharmacology 1994, 113:699-702.
74. Oriowo M.A. Different atypical beta-adrenoceptors mediate isoprenaline-induced relaxation in vascular and non-vascular smooth muscles. Life Sciences 1995, 56:L269-L275.
75. Pelat M., Verwaerde P., Galitzky J., et al. High isoproterenol doses are required to activate beta3-adrenoceptor-mediated functions in dogs. The Journal of Pharmacology and Experimental Therapeutics 2003, 304:246-253.
76. Pietri-Rouxel F., Strosberg A.D. Pharmacological characteristics and species-related variations of beta 3-adrenergic receptors. Fundamental & Clinical Pharmacology 1995, 9:211-218.
77. Popp B.D., Hutchinson D.S., Evans B.A., et al. Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors. European Journal of Pharmacology 2004, 484:323-331.
78. Rasmussen H.H., Figtree G.A., Krum H., et al. The use of beta3-adrenergic receptor agonists in the treatment of heart failure. Current Opinion in Investigational Drugs 2009, 10:955-962.
79. Rautureau Y., Toumaniantz G., Serpillon S., et al. Beta 3-adrenoceptor in rat aorta: Molecular and biochemical characterization and signalling pathway. British Journal of Pharmacology 2002, 137:153-161.
80. Rohrer D.K., Chruscinski A., Schauble E.H., et al. Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors. The Journal of Biological Chemistry 1999, 274:16701-16708.
81. Rouget C., Barthez O., Goirand F., et al. Stimulation of the ADRB3 adrenergic receptor induces relaxation of human placental arteries: Influence of preeclampsia. Biology of Reproduction 2006, 74:209-216.
82. Rouget C., Breuiller-Fouche M., Mercier F.J., et al. The human near-term myometrial beta3-adrenoceptor but not the beta2-adrenoceptor is resistant to desensitisation after sustained agonist stimulation. British Journal of Pharmacology 2004, 141:831-841.
83. Rozec B., Erfanian M., Laurent K., et al. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. Journal of the American College of Cardiology 2009, 53:1532-1538.
84. Rozec B., Gauthier C. Beta3-adrenoceptors in the cardiovascular system: Putative roles in human pathologies. Pharmacol Therapeutica 2006, 111:652-673.
85. Rozec B., Quang T.T., Noireaud J., et al. Mixed beta3-adrenoceptor agonist and alpha1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta. British Journal of Pharmacology 2006, 147:699-706.
86. Rozec B., Serpillon S., Toumaniantz G., et al. Characterization of beta3-adrenoceptors in human internal mammary artery and putative involvement in coronary artery bypass management. Journal of the American College of Cardiology 2005, 46:351-359.
87. Sato M., Horinouchi T., Hutchinson D.S., et al. Ligand-directed signaling at the beta3-adrenoceptor produced by 3-(2-ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2s-2-propanol oxalate (SR59230A) relative to receptor agonists. Molecular Pharmacology 2007, 72:1359-1368.
88. Sato M., Hutchinson D.S., Evans B.A., et al. Functional domains of the mouse beta(3)-adrenoceptor associated with differential G-protein coupling. Biochemical Society Transactions 2007, 35:1035-1037.
89. Shafiei M., Omrani G., Mahmoudian M. Coexistence of at least three distinct beta-adrenoceptors in human internal mammary artery. Acta Physiologica Hungarica 2000, 87:275-286.
90. Shen Y.T., Cervoni P., Claus T., et al. Differences in beta3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. The Journal of Pharmacology and Experimental Therapeutics 1996, 278:1435-1443.
91. Shen Y.T., Zhang H., Vatner S.F. Peripheral vascular effects of beta-3 adrenergic receptor stimulation in conscious dogs. The Journal of Pharmacology and Experimental Therapeutics 1994, 268:466-473.
92. 2+ current. The Journal of Clinical Investigation 2008, 118:3219-3227.
93. Soeder K.J., Snedden S.K., Cao W., et al. The beta3-adrenergic receptor activates mitogen-activated protein kinase in adipocytes through a gi-dependent mechanism. The Journal of Biological Chemistry 1999, 274:12017-12022.
94. Stoleru L., Wijns W., van E.C., et al. Effects of D-nebivolol and L-nebivolol on left ventricular systolic and diastolic function: Comparison with D-L-nebivolol and atenolol. Journal of Cardiovascular Pharmacology 1993, 22:183-190.
95. Strosberg A.D. Structure and function of the beta 3-adrenergic receptor. Annual Review of Pharmacology and Toxicology 1997, 37:421-450.
96. Tagaya E., Tamaoki J., Takemura H., et al. Atypical adrenoceptor-mediated relaxation of canine pulmonary artery through a cyclic adenosine monophosphate-dependent pathway. Lung 1999, 177:321-332.
97. Takahashi H., Yoshida T., Nishimura M., et al. Beta-3 adrenergic agonist, BRL-26830a, and alpha/beta blocker, arotinolol, markedly increase regional blood flow in the brown adipose tissue in anesthetized rats. Japanese Circulation Journal 1992, 56:936-942.
98. Tavernier G., Barbe P., Galitzky J., et al. Expression of beta3-adrenoceptors with low lipolytic action in human subcutaneous white adipocytes. The Journal of Lipid Research 1996, 37:87-97.
99. Tavernier G., Galitzky J., Bousquet-Melou A., et al. The positive chronotropic effect induced by BRL 37344 and CGP 12177, two beta-3 adrenergic agonists, does not involve cardiac beta adrenoceptors but baroreflex mechanisms. The Journal of Pharmacology and Experimental Therapeutics 1992, 263:1083-1090.
100. Tavernier G., Toumaniantz G., Erfanian M., et al. Beta3-adrenergic stimulation produces a decrease of cardiac contractility ex vivo in mice overexpressing the human beta3-adrenergic receptor. Cardiovascular Research 2003, 59:288-296.
101. Trochu J.N., Leblais V., Rautureau Y., et al. Beta 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. British Journal of Pharmacology 1999, 128:69-76.
102. Ursino M.G., Vasina V., Raschi E., et al. The beta3-adrenoceptor as a therapeutic target: Current perspectives. Pharmacological Research 2009, 59:221-234.
103. van der Heyden M.A., Wijnhoven T.J., Opthof T. Molecular aspects of adrenergic modulation of the transient outward current. Cardiovascular Research 2006, 71:430-442.
104. van Spronsen A., Nahmias C., Krief S., et al. The promoter and intron/exon structure of the human and mouse beta 3-adrenergic-receptor genes. European Journal of Biochemistry 1993, 213:1117-1124.
105. Varghese P., Harrison R.W., Lofthouse R.A., et al. Beta(3)-adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility. The Journal of Clinical Investigation 2000, 106:697-703.
106. Viard P., Macrez N., Coussin F., et al. Beta-3 adrenergic stimulation of L-type ca(2+) channels in rat portal vein myocytes. British Journal of Pharmacology 2000, 129:1497-1505.
107. Walston J., Lowe A., Silver S.K., et al. The beta3-adrenergic receptor in the obesity and diabetes prone rhesus monkey is very similar to human and contains arginine at codon 64. Gene 1997, 188:207-213.
108. Walston J., Silver K., Bogardus C., et al. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. The New England Journal of Medicine 1995, 333:343-347.
109. Wheeldon N.M., McDevitt D.G., Lipworth B.J. Investigation of putative cardiac beta 3-adrenoceptors in man. The Quarterly Journal of Medicine 1993, 86:255-261.
110. Wheeldon N.M., McDevitt D.G., Lipworth B.J. Cardiac effects of the beta3-adrenoceptor agonist BRL35135 in man. British Journal of Clinical Pharmacology 1994, 37:363-369.
111. Wheeldon N.M., McDevitt D.G., McFarlane L.C., et al. Beta-adrenoceptor subtypes mediating the metabolic effects of BRL 35135 in man. Clinical Sciences (London) 1994, 86:331-337.
112. Yousif M.H., Oriowo M.A. BRL 37344 inhibited adrenergic transmission in the rat portal vein via atypical beta-adrenoceptors. Pharmacological Research 2002, 45:313-317.
113. Zhang C., Williams M.A., Edwards K.L., et al. Trp64arg polymorphism of the beta3-adrenergic receptor gene, pre-pregnancy obesity and risk of pre-eclampsia. The Journal of Maternal-Fetal & Neonatal Medicine 2005, 17:19-28.
114. Zhang Z.S., Cheng H.J., Onishi K., et al. Enhanced inhibition of L-type ca2+ current by beta3-adrenergic stimulation in failing rat heart. The Journal of Pharmacology and Experimental Therapeutics 2005, 315:1203-1211.
115. Zhang Y.H., Zhang M.H., Sears C.E., et al. Reduced phospholamban phosphorylation is associated with impaired relaxation in left ventricular myocytes from neuronal NO synthase-deficient mice. Circulation Research 2008, 102:242-249.